Logo
Q

Qubit Pharmaceuticals

69 employees

Qubit Pharmaceuticals brings unparalleled accuracy and precision to drug discovery and design, using quantum physics to develop life-changing treatments for major diseases. We leverage our technologies and expertise to advance 7 fully owned drug discovery programs focusing on cancer resistance and escapement, a growing concern in aging populations, and chronic inflammatory diseases. We also co-develop programs with academia and pharmaceutical partners. Our proprietary ATLAS drug discovery platform unites our technologies based on 30 years of research from renowned scientists and founders, Louis Lagardère (Sorbonne University and CNRS), Matthieu Montes (CNAM), Jean-Philip Piquemal (Sorbonne University and CNRS), Jay Ponder (Washington University in St Louis), Pengyu Ren (University of Texas at Austin). Their multidisciplinary team of 60 experts, led by CEO Robert Marino, works from Paris, France, Boston, USA - with a team based in Chicago, USA.

Investor insights

Funding rounds participated in

$17M sweet spot round size

Investor type

Privately Held

Basic info

Industry

Software Development

Sectors

Software Development

Date founded

2020

Funding rounds raised

Total raised

$17M

from investors over 1 rounds

Q

Qubit Pharmaceuticals raised $17M on July 10, 2022

FAQ